| All patients (n = 1042) | Axial group (n = 828) | Extra-axial group (n = 214) | p-value |
---|---|---|---|---|
Age at starting TNFi (years, %) | 38.32 (13.08) | 38.18 (12.76) | 38.85 (14.28) | 0.618 |
Sex (male, %) | 793 (76.1) | 651 (78.6) | 142 (66.4) | 0.001 |
Late onset (age ≥ 40 years, %) | 329 (31.6) | 247 (29.8) | 82 (38.3) | 0.034 |
Long disease duration (≥ 2 years, %) | 426 (40.9) | 380 (45.9) | 46 (21.5) | < 0.001 |
HLA-B27 positivity (%) | 929 (89.2) | 740 (89.4) | 189 (88.3) | 0.782 |
Inflammatory back pain (%) | 887 (85.1) | 704 (85.0) | 183 (85.5) | 0.943 |
Radiographic sacroiliitis (%) | 934 (89.6) | 745 (90.0) | 189 (88.3) | 0.618 |
Peripheral arthritis (%) | 388 (37.2) | 203 (24.5) | 185 (86.4) | < 0.001 |
Enthesitis (%) | 218 (20.9) | 68 (8.2) | 150 (70.1) | < 0.001 |
Uveitis (%) | 222 (21.3) | 168 (20.3) | 54 (25.2) | 0.197 |
Psoriasis (%) | 27 (2.6) | 16 (1.9) | 11 (5.1) | 0.029 |
IBD (%) | 13 (1.2) | 9 (1.1) | 4 (1.9) | 0.618 |
Good response to NSAIDs (%) | 358 (34.4) | 212 (25.6) | 146 (68.2) | < 0.001 |
csDMARD use (%) | 107 (10.3) | 75 (9.1) | 32 (15.0) | 0.029 |
NSAID use (%) | 904 (86.8) | 714 (86.2) | 190 (88.8) | 0.486 |
SJC | 0.65 (2.28) | 0.50 (2.37) | 1.21 (1.80) | < 0.001 |
TJC | 1.04 (3.06) | 0.71 (2.67) | 2.32 (4.00) | < 0.001 |
BASDAI | 6.03 (1.91) | 5.94 (1.92) | 6.37 (1.81) | 0.005 |
BASFI | 3.47 (2.56) | 3.42 (2.56) | 3.66 (2.56) | 0.305 |
ASDAS-ESR | 3.74 (1.03) | 3.65 (1.00) | 4.05 (1.08) | < 0.001 |
ASDAS-CRP | 3.66 (1.02) | 3.61 (1.00) | 3.87 (1.07) | 0.003 |
ESR (mm/h) | 37.87 (30.03) | 35.65 (28.76) | 46.46 (33.21) | < 0.001 |
CRP (mg/dL) | 2.27 (2.95) | 2.11 (2.74) | 2.89 (3.60) | 0.006 |